Phase 2 Start~month
Phase 2 Start: Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combinatio
- Company
- ImmunityBio, Inc. (IBRX)
- Drug
- nogapendekin
- Indication
- Septic Shock; Critical Illness; Sepsis
Other upcoming events for IBRX
Phase 2 StartPhase 2 Start: Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combinatio
Phase 2 StartPhase 2 Start: Open-Label, Single-Arm Phase 2 Study Of Nogapendekin Alfa Inbakicept, PD-L1 T-HaNK, And Bevacizumab
Phase 3 ReadoutPhase 3 Topline: Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Faile
Phase 3 ReadoutPhase 3 Topline: Phase 3, Randomized, Open-Label Study of Nogapendekin Alfa Inbakicept in Combination With Standard o
Patent ExpiryPatent/Exclusivity Expiry: KHAPZORY
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.